Simulations Plus, Inc. (SLP)
$
20.49
+0.14 (0.68%)
Key metrics
Financial statements
Free cash flow per share
0.6479
Market cap
409.9 Million
Price to sales ratio
5.0999
Debt to equity
0.0058
Current ratio
5.1106
Income quality
-0.2248
Average inventory
0
ROE
-0.3715
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Simulations Plus, Inc. develops drug discovery and development software that leverages artificial intelligence and machine learning technologies for modeling, simulation, and prediction of molecular properties globally. The company reported an earnings per share (EPS) of -$3.22 indicating its profitability on a per-share basis. The income before tax ratio stands at -0.88 reflecting the pre-tax margin, while the cost of revenue amounts to $32,958,000.00 showcasing its production and operational expenses. The company's EBITDA is reported at -$70,729,000.00 serving as a key indicator of operational profitability. Additionally, the gross profit ratio is 0.58 highlighting the efficiency of the company's production and sales operations. Operating through segments such as Simulations Plus, Cognigen, DILIsym, and Lixoft, the company provides products like GastroPlus, which simulates drug interactions in humans and animals, along with various simulation tools like DDDPlus and MembranePlus. Moreover, it offers advanced mechanistic and mathematical models through products like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Simulations Plus also features an Absorption, Distribution, Metabolism, Excretion, and Toxicity Predictor, and MedChem Designer, supplemented by MonolixSuite and PKPlus modeling products. Alongside, it offers consulting and contract research services that support pharmacometrics studies and regulatory submissions. Currently, the stock is affordable at $15.25 making it suitable for budget-conscious investors. It has a low average trading volume of 529,903.00 indicating lower market activity. With a market capitalization of $412,762,116.00 the company is classified as a small-cap player. Simulations Plus is a key player in the Medical - Healthcare Information Services industry, contributing significantly to the overall market landscape. Furthermore, it belongs to the Healthcare sector, driving innovation and growth within its field. As the company continues to make strides in drug development technologies, it presents opportunities for investors looking to engage in a forward-thinking and strategically positioned entity in the life sciences domain.
Is Simulations Plus, Inc. (SLP) a good investment?
Investing in Simulations Plus, Inc. (SLP) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bullish outlook. Always conduct your own research before investing.
What is Simulations Plus, Inc. (SLP)'s stock forecast?
Analysts predict Simulations Plus, Inc. stock to fluctuate between $12.39 (low) and $37.67 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Simulations Plus, Inc.'s market capitalization?
As of 2025-12-04, Simulations Plus, Inc.'s market cap is $412,762,116, based on 20,144,564 outstanding shares.
How does Simulations Plus, Inc. compare to competitors like Nvidia Corp?
Compared to Nvidia Corp, Simulations Plus, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Simulations Plus, Inc. pay dividends?
Simulations Plus, Inc. pays dividends. The current dividend yield is 0.60%, with a payout of $0.06 per share.
How can I buy Simulations Plus, Inc. (SLP) stock?
To buy Simulations Plus, Inc. (SLP) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for SLP. Place an order (Market, Limit, etc.).
What is the best time to invest in Simulations Plus, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bullish trend based on economic conditions and company performance.
Has Simulations Plus, Inc. stock ever split?
Simulations Plus, Inc.'s last stock split was 2:1 on 2007-10-02.
How did Simulations Plus, Inc. perform in the last earnings report?
Revenue: $79,179,000 | EPS: -$3.22 | Growth: -744%.
Where can I find Simulations Plus, Inc.'s investor relations reports?
Visit https://www.simulations-plus.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Simulations Plus, Inc.?
You can explore historical data from here
What is the all-time high and low for Simulations Plus, Inc. stock?
All-time high: $67.59 (2022-08-08) | All-time low: $12.39 (2025-07-18).
What are the key trends affecting Simulations Plus, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
seekingalpha.com
Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP's services help across discovery, development, and clinical operations. Software remains their main economic driver with higher margins. Services are growing faster and gradually increasing their share of total revenues but have lower margins.
seekingalpha.com
Simulations Plus, Inc. (SLP) Q4 2025 Earnings Call Transcript
prnewswire.com
NEWTOWN, Pa. , Nov. 28, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Simulations Plus, Inc. (NASDAQ: SLP), resulting from allegations of providing potentially misleading business information to the investing public.
zacks.com
Simulations Plus (SLP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
zacks.com
The consensus price target hints at a 33.6% upside potential for Simulations Plus (SLP). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
prnewswire.com
NEWTOWN, Pa. , Nov. 10, 2025 /PRNewswire/ -- Edelson Lechtzin LLP is investigating potential violations of the federal securities laws involving Simulations Plus, Inc. ("Simulations Plus") (NASDAQ: SLP), resulting from allegations of providing potentially misleading business information to the investing public.
globenewswire.com
Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Simulations Plus (SLP) To Contact Him Directly To Discuss Their Options If you purchased or acquired stock in Simulations Plus and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
zacks.com
The mean of analysts' price targets for Simulations Plus (SLP) points to a 25.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
prnewswire.com
NEW YORK , Oct. 28, 2025 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public. So What: If you purchased Simulations Plus securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.
globenewswire.com
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Simulations Plus, Inc. (NASDAQ: SLP) resulting from allegations that Simulations Plus may have issued materially misleading business information to the investing public.
See all news
